Fr. 179.00

Medullary Thyroid Carcinoma - Biology, management, and treatment of sporadic and hereditary MTC

English · Hardback

Shipping usually within 6 to 7 weeks

Description

Read more

After 10 years, this second edition is extensively rewritten and updated and provides a source of information concerning all aspects of medullary thyroid carcinoma, including comprehensive actual references for interested scientists.
Medullary thyroid carcinoma (MTC) is a rare unique tumor which differs from other thyroid tumors by originating from the neuroendocrine C-cell, secreting the specific tumor marker calcitonin. MTC is associated in about 25% of cases with multiple endocrine neoplasia type 2, an autosomal dominant familial disorder causing tumors within various endocrine glands. The molecular genetics of tumor development is clarified: hereditary as well as sporadic MTC are linked to mutations in the RET proto- oncogene coding for a tyrosine kinase. These RET mutations serve as a genetic marker for hereditary MTC and allow for prophylactic thyroidectomy in gene carriers. The RET-tyrosine kinase is also a new therapeutic target using selective  tyrosine kinase inhibitors improving the outcome of advanced metastasized MTC. 
This book will be an ideal source of up-to-date information for a wide range of practitioners, including endocrinologists, oncologists, internal medicine specialists, geneticists, and nuclear medicine physicians.

List of contents

What is new?.- Thyroid C-Cell Biology and Oncogenic Transformation.- Histopathology of C cells and medullary thyroid carcinoma.- Epidemiology and clinical presentation of Medullary Thyroid Carcinoma.- Medullary thyroid carcinoma: Imaging.- Calcitonin as a Biomarker for Medullary Thyroid Carcinoma.- Hereditary Medullary Thyroid Cancer, Genotype phenotype correlation.- Pheochromocytomas in Multiple Endocrine Neoplasia type 2.- Primary hyperparathyroidism in Multiple Endocrine Neoplasia 2 Syndrome.- Surgical treatment of  medullary thyroid carcinoma.- Long term follow up in medullary thyroid carcinoma.- Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.

About the author

n/a

Summary

After 10 years, this second edition is extensively rewritten and updated and provides a source of information concerning all aspects of medullary thyroid carcinoma, including comprehensive actual references for interested scientists.
Medullary thyroid carcinoma (MTC) is a rare unique tumor which differs from other thyroid tumors by originating from the neuroendocrine C-cell, secreting the specific tumor marker calcitonin. MTC is associated in about 25% of cases with multiple endocrine neoplasia type 2, an autosomal dominant familial disorder causing tumors within various endocrine glands. The molecular genetics of tumor development is clarified: hereditary as well as sporadic MTC are linked to mutations in the RET proto- oncogene coding for a tyrosine kinase. These RET mutations serve as a genetic marker for hereditary MTC and allow for prophylactic thyroidectomy in gene carriers. The RET-tyrosine kinase is also a new therapeutic target using selective  tyrosine kinase inhibitors improving the outcome of advanced metastasized MTC. 
This book will be an ideal source of up-to-date information for a wide range of practitioners, including endocrinologists, oncologists, internal medicine specialists, geneticists, and nuclear medicine physicians.

Product details

Assisted by Frank-Raue (Editor), Karin Frank-Raue (Editor), Friedhelm Raue (Editor)
Publisher Springer, Berlin
 
Languages English
Product format Hardback
Released 13.05.2025
 
EAN 9783031803956
ISBN 978-3-0-3180395-6
No. of pages 307
Illustrations XVI, 307 p. 48 illus., 30 illus. in color.
Series Recent Results in Cancer Research
Subjects Natural sciences, medicine, IT, technology > Medicine > Clinical medicine

Nuklearmedizin, Endokrinologie, Pädiatrie, Genetik, Medizin, Pediatrics, Endocrinology, Oncology, calcitonin, nuclear medicine, Medical Genetics, Primary hyperparathyroidism, Pheochromocytoma, tyrosinekinase inhibitor, Multiple Endocrine Neoplasia Type 2

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.